PW
RLMD icon

Pandora Wealth’s Relmada Therapeutics RLMD Stock Holding History

Pandora Wealth’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$96.6K Hold
20,000
– – 0.06% 113
2025
Q3 		$40.2K Hold
20,000
– – 0.02% 152
2025
Q2 		$12K Hold
20,000
– – 0.01% 189
2025
Q1 		$5.4K Buy
+20,000
New +$6.63K ﹤0.01% 205

Other funds holding RLMD

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $273M AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
SSC
Spruce Street Capital New York $416M AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Pandora Wealth's RLMD Position: Q4 2025 in Review

Pandora Wealth held its Relmada Therapeutics (RLMD) position steady in Q4 2025 at 20,000 shares worth $96.6K. The position accounts for 0.06% of the portfolio, ranked #113.

Pandora Wealth first reported a position in RLMD in Q1 2025 and has held it in 4 quarters since. 78 funds tracked by Wall St. Rank hold RLMD as of Q4 2025.

  • Pandora Wealth held 20,000 shares of Relmada Therapeutics worth $96.6K as of Q4 2025.
  • Pandora Wealth left its Relmada Therapeutics share count unchanged in Q4 2025.
  • Relmada Therapeutics made up 0.06% of Pandora Wealth's portfolio in Q4 2025, its #113 holding.
  • Pandora Wealth first reported a position in Relmada Therapeutics in Q1 2025 and has held it in 4 quarters since.
  • 78 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q4 2025.

Based on Pandora Wealth's 13F filing for Q4 2025, filed 4 Feb 2026.